Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.33 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20739215 | 1.00 | TUBB1 (0.59) | TUBB1HDAC1CA2CA1FOLH1 | |
| SCHEMBL20739239 | 1.00 | TUBB1 (0.59) | TUBB1HDAC1CA2CA1FOLH1 | |
| SCHEMBL22316590 | 1.00 | TUBB1 (0.59) | TUBB1HDAC1CA2CA1FOLH1 | |
| SCHEMBL22283980 | 0.94 | TUBB1 (0.62) | TUBB1HDAC1CA2CA1FOLH1 | |
| SCHEMBL30779240 | 0.94 | TUBB1 (0.62) | TUBB1HDAC1CA2CA1FOLH1 | |
| SCHEMBL20739123 | 0.94 | TUBB1 (0.61) | TUBB1HDAC1CA2CA1FOLH1 | |
| SCHEMBL22315894 | 0.94 | TUBB1 (0.61) | TUBB1HDAC1CA2CA1FOLH1 | |
| SCHEMBL22283982 | 0.94 | TUBB1 (0.61) | TUBB1HDAC1CA2CA1FOLH1 | |
| SCHEMBL24575157 | 0.93 | TUBB1 (0.60) | TUBB1HDAC1FOLH1ADAMTS4ADAMTS5 | |
| SCHEMBL22316491 | 0.93 | TUBB1 (0.60) | TUBB1HDAC1FOLH1ADAMTS4ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | FCGRT, QARS1, INHA | TUBB1 436/4885HDAC1 768/4885CA2 3688/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | TUBB1 436/4885HDAC1 768/4885CA2 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.